Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Clinical trial NCT00522457 · TERMINATED
Trial details
- NCT number
- NCT00522457
- Sponsor
- Neovii Biotech
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-01-01
- Primary completion
- 2009-12-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.